Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment

Psychopharmacology

Volumn 194, Issue 1, 2007, Pages 1-10

  Davidson, Dena ^a   Wirtz, Philip W ^b   Gulliver, Suzy Bird ^c   Longabaugh, Richard ^d  

^a INDIANA UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Alcohol dependence; Alcohol Naltrexone; Broad spectrum treatment; Motivational enhancement therapy

Indexed keywords

ALCOHOL; NALTREXONE; PLACEBO;

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ARTICLE; CHRONOPHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG DEPENDENCE TREATMENT; FATIGUE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; ANXIETY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NAUSEA; PATIENT COMPLIANCE; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 34548027285     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0807-y     Document Type: Article

References (41)

1. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of out-patient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 11:1758-1764
2. Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, Roberts JS (2001) Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21:72-77
3. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R (2005) Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 25:349-357
4. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen J, Gustafsson L, Halldin, Nilsson G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27:1142-1149
5. Biener L, Abrams DB (1991) The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol 10:360-365
6. Bohn MJ, Kranzler HR, Beazoglou D, Staehler BA (1994) Naltrexone and brief counseling to reduce heavy drinking. Am J Addictions 3:91-99
7. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000) A multicenter, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35:587-593
8. COMBINE research group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. The combine study: a randomized controlled trial. JAMA 295:2003-2017
9. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Quellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273-3277
10. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J (2003) Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6:566-573
11. Davidson D, Saha C, Scifres S, Fyffe J, O'Connor S, Selzer C (2004) Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers. Addict Behav 29:1253-1258
12. Davidson D, Gulliver S-B, Longabaugh R, Wirtz PW, Swift R (2007) Building better CBT: Is broad spectrum treatment more effective than motivational enhancement therapy for alcohol dependent patients treated with naltrexone. J Stud Alcohol Drugs 68(2):238-247
13. Feinn R, Kranzler HR (2005) Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcohol Clin Exp Res 29:983-988
14. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Petinati HM, Silverman BL, Loewy JW, Ehrich EW (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 293:1617-1625
15. Gastpar M, Udo B, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22:592-598
16. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Seguara L, Trujols J, Casa M (2002) A double-blind placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: Results from a multicenter clinical trial. Alcohol Clin Exp Res 26:1381-1387
17. Gulliver SB, Longabaugh R, Davidson D, Swift R (2005) The development of a broad spectrum treatment for patients with alcohol dependence in early recovery. adapting CBT for recalcitrant populations. Cogn Behav Pract 12:53-63
18. Heinala P, Alho H, Kuoppasalmi K, Sinclair D, Kiianmaa K, Lonngvist J (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21:287-292
19. Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22:493-503
20. Kranzler HR, Wesson DR, Billot L for the DrugAbuse Sciences Naltrexone Depot Study Group (2004) Naltrexone depot for treatment of alcohol dependence; a multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical & Experimental Research. Vol 28(7), 1051-1059
21. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. New Engl J Med 345:1734-1739
22. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone is alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. Med J Aust 176:530-534
23. Longabaugh R, Woolard RE, Nirenberg TD, Minugh AP, Becker B, Clifford PR, Carty K, Licsw, Sparadeo F, Gogineni A (2001) Evaluating the effects of a brief motivational intervention for injured drinkers in the emergency department. J Stud Alcohol Drugs 62:806-811
24. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. ACER 30:1288-1296
25. Miller WR, Zweben A, DiClemente CC, Rychtarik RG (1995) Motivational enhancement therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. National Institute on Alcohol Abuse and Alcoholism Project MATCH Monograph Series, vol. 2, NIAAA, Rockville, MD, USA
26. Monterosso JR, Flannery BA, Poettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addict 10:258-268
27. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 25:1634-1647
28. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond J (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96:1565-1573
29. Namkoong K, Farren CK, O'Connor PG, O'Malley SS (1999) Measurement of compliance with naltrexone in the treatment of alcohol dependence: Research and clinical implications. J Clin Psychiatry 60:446-453
30. O'Brien CP, Volpicelli LA, Volpicelli JR (1996) Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 13:35-39
31. Oslin DW, Liberto JG, O'Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5:324-332
32. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volicelli JR, O'Brian CP (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552
33. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 46:881-887
34. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B (1996) Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53:217-224
35. O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O'Connor PG (2003) Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care. Arch Intern Med 163:1695-1704
36. Oswald LM, Wand GS (2004) Opioids and alcoholism. Physiol Behav 81:339-358
37. SAS Institute (1999) SAS/STAT® user's guide (version 8). SAS Institute, Cary, NC, USA
38. Sobell LC, Sobell MB (1996) Alcohol timeline follow-back (TLFB) users' manual. Addiction Research Foundation, Toronto
39. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880
40. Volpicelli JR, Clay KL, Watson NT, O'Brien CP (1995) Naltrexone in the treatment of alcoholism: Predicting response to naltrexone. J Clin Psychiatry 56:39-44
41. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Arch Gen Psychiatry 54:737-742